Clinical Trial Update: Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children [Phase 1]

View source ↗

Summary

This Phase 1 trial assessed the safety and immune response of a recombinant live attenuated Parainfluenza Type 3 vaccine in healthy infants and children and has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parainfluenza Virus Infection

Drugs mentioned

• Parainfluenza Type 3 vaccine (recombinant live attenuated) (recombinant live attenuated Parainfluenza Type 3 virus vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Paramyxoviridae Infections, Virus Diseases | Phase 1 | Status: COMPLETED